Despite robust evidence supporting aggressive LDL-cholesterol reduction for the prevention of atherosclerotic cardiovascular disease (ASCVD), substantial gaps persist between guideline recommendations and real-world treatment intensification. Many high-risk and very high-risk patients fail to achieve recommended LDL-C thresholds, leaving them vulnerable...